Zydus Lifesciences Posts Stellar Q3 FY26 with 30% Revenue Jump, Settles Key US Legal Dispute

Zydus Lifesciences Limited has reported a stellar third quarter for fiscal year 2026, with consolidated revenues soaring by 30% year-on-year to ₹68.6 billion. The company's operational profitability also saw a significant boost, with EBITDA climbing 31% year-on-year to ₹18.2 billion, leading to a healthy EBITDA margin of 26.5%, a 20 basis points improvement over the previous year. Consolidated net profit stood at ₹11.1 billion, marking a 9% increase year-on-year, adjusted for exceptional expenses related to acquisitions.

This impressive performance was driven by strong execution across all key business segments, including significant contributions from recent strategic acquisitions. The integration of Amplitude Surgical and Comfort Click businesses has bolstered Zydus's offerings in medical devices and consumer wellness, respectively. The consumer wellness segment, in particular, saw revenues surge by 113% year-on-year, largely benefiting from the full quarter consolidation of the Comfort Click business.

Key Growth Pillars and Strategic Moves

The company's diversified global presence played a crucial role. The US business reported an 11% volume growth in the calendar year, outperforming the market, and saw 18 Abbreviated New Drug Applications (ANDAs) filed, with 8 approvals and 4 new product launches in the quarter. The specialty segment launched BEIZRAY and received USFDA approval for Zycubo. India business achieved a robust 14% year-on-year growth in its branded formulation segment, while international markets, especially emerging markets and Europe, reported a strong 38% year-on-year revenue growth, reaching ₹7.9 billion.

Zydus is also actively building its innovation pipeline. Plans include filing an NDA for Saroglitazar Magnesium in the US for PBC indication, advancing Phase III trials for its second biosimilar ADC, and initiating Phase II trials for a Bivalent Typhoid Conjugate vaccine, with ambitious targets for a ₹1000 crore+ vaccine business within 3-4 years.

The company's strategic M&A approach continues, aiming for 1-2 deals annually to foster specialty-driven diversification, particularly in the US market.

Mirabegron Settlement and Past Regulatory Scrutiny

A significant development from the quarter is the settlement of Zydus's US patent litigation concerning its generic Mirabegron (marketed as Myrbetriq by Astellas Pharma). Zydus will pay Astellas Pharma $120 million, plus a per-unit licensing fee until September 2027, to resolve the dispute. This settlement allows Zydus to continue marketing its generic Mirabegron in the US, concluding all related litigation. This follows a similar settlement by Lupin, highlighting a trend of patent dispute resolutions in the generics space.

It's important to note Zydus's history with regulatory compliance. In the past, particularly in 2019, 2022, and 2024, the company faced FDA warning letters and Form 483 observations for its manufacturing facilities in India concerning good manufacturing practices. While the company has stated it has addressed these issues and obtained approvals for some facilities, this background underscores the importance of ongoing regulatory adherence for pharmaceutical companies operating in key global markets.

Furthermore, the company's revenue from Lenalidomide (Revlimid) is expected to cease from the next quarter, marking the business completion for FY26. The net debt stands at ₹3,000 crore, a result of recent acquisitions, which management considers manageable.

Outlook and Peer Comparison

Management expressed confidence in sustained double-digit growth across businesses, projecting EBITDA margins to remain above 23% in Q4 FY26. The company aims to build a substantial vaccine business and expand its specialty and 505(b)(2) pipeline.

Compared to its peers, Zydus's 30% revenue growth in Q3 FY26 significantly outpaces competitors like Dr. Reddy's Laboratories (4.4% growth) and Sun Pharmaceutical Industries (15.1% growth) for the same period. Cipla reported flat revenue growth. While Zydus's profit growth (adjusted) was 9%, Sun Pharma reported 16% profit growth, and Dr. Reddy's saw a 14% decline in net profit. Zydus's aggressive growth strategy, fueled by acquisitions and product launches, appears to be yielding strong top-line results, though it also brings integration challenges and increased debt.

Peer Comparison

• Sun Pharma: Reported Q3 FY26 revenue of ₹15,469 crore (+15.1% YoY) and net profit of ₹3,369 crore (+16.0% YoY). It maintained a strong EBITDA margin of 31.9% and declared an interim dividend of ₹11/share.
• Dr. Reddy's: Posted Q3 FY26 revenue of ₹8,727 crore (+4.4% YoY) but saw net profit decline 14% YoY to ₹1,210 crore. Gross margins moderated due to lower Lenalidomide sales and price erosion.
• Cipla: Reported Q3 FY26 revenue of approximately ₹7,000 crore (largely flat YoY) and a significant 57% drop in net profit to ₹676 crore, primarily due to production halts for key drugs and higher R&D spend. The company maintains a strong net cash position.

Zydus's revenue growth stands out, demonstrating successful integration of its recent large-scale acquisitions and strong organic performance in key markets. However, managing its increased debt and navigating the ongoing regulatory landscape will be critical going forward.